<p>Elevated levels of pre-treatment lactate dehydrogenase are an unfavorable predictor factor in patients with EML4-ALK rearrangement non-small cell lung cancer treated with crizotinib</p>

Hongge Liang(Chinese Academy of Medical Sciences & Peking Union Medical College), Mengzhao Wang(Chinese Academy of Medical Sciences & Peking Union Medical College), Di Ma(Chinese Academy of Medical Sciences & Peking Union Medical College), Yan Xu(Chinese Academy of Medical Sciences & Peking Union Medical College), Junling Li(Tianjin Academy of Agricultural Sciences), Xiaoyan Liu(Capital Medical University), Jing Zhao(University of Electronic Science and Technology of China), Wei Zhong(Chinese Academy of Medical Sciences & Peking Union Medical College), Minjiang Chen(Chinese Academy of Medical Sciences & Peking Union Medical College)
Cancer Management and Research
September 1, 2019
Cited by 6


Related Papers